Genomics

#Biotechnology #Drug development #Drug discovery #Genomics #Synthetic biology #Synthetic DNA

Synthetic biology: Shaping the future of drug discovery 

By Lu Rahman  There are some exciting developments happening in synthetic biology and as a result the sector is highly attractive from an investment perspective. Using synthetic DNA to develop drugs and to better understand the toxic effects of them is a key driver for this market. BCC Research reports… Read More

#Exclusive Content #Trends & Analysis

AI brain
#AI / data analytics / healthtech / informatics #ALS #Biotechnology #Clinical trials #Drug discovery #Genomics

AI-driven biotech initiates Phase I trial for ALS drug 

Verge Genomics, a clinical-stage, tech-enabled biotechnology company using artificial intelligence (AI) and human data to transform drug discovery, has announced today that the first subject has been dosed in a Phase I clinical trial of VRG50635 for amyotrophic lateral sclerosis (ALS).  VRG50635 is a small molecule inhibitor… Read More

#News

Laboratory studies student
#Genomics #Laboratory #Next generation sequencing #Undergraduate course #US

New genomics lab to offer NGS undergraduate course

A new laboratory specialising in genomics is set to open at the North Carolina Research Campus (NCRC) in Kannapolis, North Carolina. The Bill and Shari Graham Genomics Laboratory is a collaborative project from Catawba College and Eremid Genomic Services. The Lab will offer the only undergraduate next-generation DNA sequencing (NGS)… Read More

#News

Cancer research in lab
#Cancer research #Collaboration #Genomics #Oncology

Strategic collaboration to enhance targeted oncology programmes

Oncology platform company Tavros Therapeutics and biopharmaceutical company Vividion Therapeutics (a subsidiary of Bayer AG) have agreed to collaborate on four oncology targets across an initial five-year term. Tavros’ functional and computational genomics technologies are designed to uncover unique vulnerabilities within tumours to discover novel targets and biomarkers in areas… Read More

#Business & Investment #Cancer Research #News

#Diagnostics #Genomics #Personalised medicine #Precision medicine #Predictive diagnostics

Predictive diagnostics: closing the precision medicine gap

Listen to this article on the DDW podcast: Jarret Glasscock, PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time.  Precision medicine promises a paradigm shift to confidently match the right patients… Read More

#Exclusive Content

#AI #Drug Discovery 2022 #Genomics #Immunology #Nanomedicine / nanotechnology #Personalised medicine

Sharing knowledge to fuel the revolution

Here, we speak with two of the keynote speakers at this year’s Drug Discovery 2022, Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine at Imperial College London, and Rab Prinjha, VP Head of Immunology Research Unit at GlaxoSmithKline, about the insights they will be sharing and what they see as the… Read More

#Exclusive Content

#Covid-19 #DNA #Drug discovery #Genomics #Infectious diseases

This week in drug discovery (18 -22 July)

News round-up by DDW’s Reece Armstrong for 18 – 22 July Covid-19 vaccines remain effective six months after second dose  Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.   New combination therapy… Read More

#News

#AI / data analytics / healthtech / informatics #Genomics

C2i Genomics launches AI-powered cancer monitoring tests in Europe 

C2i Genomics, a cancer intelligence company, has launched its C2inform minimal residual disease (MRD) test across Europe after obtaining CE-IVD marking in the EU, UK and Switzerland.   The company also announced the completion of several clinical trials across the globe, including cancer centers in Europe, US and… Read More

#News

#Comment #ELRIG #Genomics #Innovation #Research

Comment: Innovations for tomorrow’s drug discovery 

At the end of last month, DDW’s Megan Thomas attended ELRIG’s Research & Innovation 2022: Innovations for Tomorrow’s Drug Discovery, at The King’s Centre in Oxford, UK. The four sessions addressed aspects of innovation across drug discovery and placed an emphasis on both the digital age and novel modalities: Omics… Read More

#Exclusive Content #News #Opinion

#CRISPR #Gene sequencing #Genomics

Jumpcode Genomics launches tech to improve genome sequencing  

Genome technology platform provider Jumpcode Genomics has launched technology to improve single cell transcriptional profiling and aid with scientists’ understanding of genomic sequences.   Jumpcode Genomics’ CRISPRclean Single Cell RNA Boost Kit leverages the company’s CRISPR-based technology to remove uninformative sequences from libraries, enhancing single cell… Read More

#News

#CRO #Drug development #Drug discovery #Genomics

CROs: Drug discovery expertise on hand  

Listen to this article on the DDW Podcast: Lu Rahman asks Laura Hinton, Operations Director at Gentronix, to offer some insight into the contract research organisation (CRO) market and how Gentronix is making its presence known in this sector.  Gentronix is a specialist contract research organisation (CRO) based in the UK, focused on delivering predictive toxicology products and services to global… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Genome sequencing #Genomics #Podcasts

Podcast: What can we learn from the genome?  

This is the latest episode of the free DDW podcast, “What can we learn from the genome?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW and read aloud by Megan Thomas.   The articles are called “Reproducibility in single cell… Read More

#News #Trending News

CRISPR gene editing
#3D modelling #CRISPR #DNA #Drug discovery #Gene editing #Genomics #Screening

CRISPR screening in the third dimension 

Listen to this article on the DDW Podcast: Rosie Bryan & Carlos le Sage, Horizon Discovery, explain how CRISPR-Cas9 technology has become a gold standard for functional genomics.  While efforts in the cancer genomics field have uncovered the mutational landscapes in tumours covering many types of cancer, the functional contribution of the mutated… Read More

#Editor's Choice #Exclusive Content #News

#Drug discovery #Genomics #Life sciences #Molecular Biology

Finding the right cancer drug with high-content screening

Listen to this article on the DDW Podcast: Lassi Paavolainen, Principal Investigator at the Institute for Molecular Medicine Finland (FIMM), Vilja Pietiäinen, Adjunct Professor in Cell and Molecular Biology, and Amanda Jones, Life Science Research Strategy Leader at PerkinElmer explain how functional precision medicine using ex vivo drug testing… Read More

#Editor's Choice #News

#AstraZeneca #Biobanking #Genetics #Genomics

Rare variant contribution to human disease  

Listen to this article on the DDW Podcast: Slavé Petrovski and Andrew Harper, Centre for Genomics Research, AstraZeneca, outline the implications and insight offered by the recent publication of an AstraZeneca-authored paper “Rare variant contribution to human disease in 281,104 UK Biobank exomes”.  In August 2021, Nature published the largest and most comprehensive evaluation of the… Read More

#Exclusive Content #News #Opinion #Trends & Analysis